GE Healthcare Announces Commercial Availability of New Methodology That Provides a Cancer Profile on a Single Slide
5/31/2013 2:57:24 PM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PRINCETON, N.J.--(BUSINESS WIRE)--GE Healthcare today announced at the 2013 Annual Meeting of the American Society of Clinical Oncology its plans for the commercialization of MultiOmyx™, a ground-breaking new pathology platform, using proprietary methodology to analyze multiple proteins at a single-cell level. Traditional pathology uses multiple slices from paraffin-fixed tumor samples and examines them slide by slide, which is less efficient and effective. The platform, already in use in research, will now be introduced to the clinical environment and initially available for testing through a global service offering in Hodgkin lymphoma in July 2013 in GE Healthcare’s CLIA licensed laboratory – Clarient Diagnostic Services, Inc. – a GE Healthcare Company.
Help employers find you! Check out all the jobs and post your resume.
comments powered by